Credit Suisse Upgrades AstraZeneca (AZN) to Outperform
Tweet
Share
E-mail
Get Alerts AZN Hot Sheet
Price: $92.77 --0%
Rating Summary:
19 Buy, 8 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 17 | New: 18
Rating Summary:
19 Buy, 8 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 17 | New: 18
Join SI Premium – FREE
Credit Suisse upgraded AstraZeneca (NYSE: AZN) from Neutral to Outperform.
For an analyst ratings summary and ratings history on AstraZeneca click here. For more ratings news on AstraZeneca click here.
Shares of AstraZeneca closed at $34.61 Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Upgrades M&T Bank (MTB) to Overweight
- FDA grants accelerated approval to AstraZeneca's camizestrant combo
- Peloton Interactive (PTON) PT Lowered to $10 at UBS
Create E-mail Alert Related Categories
Analyst Comments, Hot Upgrades, UpgradesRelated Entities
Credit SuisseSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
